Yumanity Therapeutics, Inc.

NasdaqCM:YMTX Stock Report

Market Cap: US$143.6m

Yumanity Therapeutics Past Earnings Performance

Past criteria checks 0/6

Yumanity Therapeutics's earnings have been declining at an average annual rate of -14.5%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 43.6% per year.

Key information

-14.5%

Earnings growth rate

42.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate43.6%
Return on equity-584.4%
Net Margin-660.7%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Yumanity Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:YMTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 225-32200
30 Jun 225-3920-1
31 Mar 226-44190
31 Dec 218-40200
30 Sep 2111-66190
30 Jun 2113-62181
31 Mar 2110-52160
31 Dec 207-51120
30 Sep 203-23100
30 Jun 200-2590
31 Mar 200-3280
31 Dec 190-3170

Quality Earnings: YMTX is currently unprofitable.

Growing Profit Margin: YMTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: YMTX is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare YMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Return on Equity

High ROE: YMTX has a negative Return on Equity (-584.37%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.